Diversified Pharma Portfolio Outperforms Single Stock for Dividends

Investment analysis of the pharmaceutical sector indicates that diversifying across multiple stocks is a safer strategy for generating a monthly dividend income of $1,000 than relying on a single high-yield asset. While a $200,000 investment in Pfizer could yield $12,000 annually due to its 6.1% yield, the company faces risks from patent expirations and earnings that do not cover its dividends.

To mitigate the risk of a dividend cut, analysts suggest a diversified portfolio requiring a total investment of $350,000. This strategy splits $70,000 each among Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen to produce a similar annual income of $12,040.

These companies face varying operational risks. Bristol Myers Squibb faces upcoming patent losses for Opdivo and Eliquis in 2028, while Amgen faces potential generic competition for Otezla in the same year. Johnson & Johnson and AbbVie are noted as Dividend Kings with yields of 2% and 2.5% respectively.